TMBR Insider Trading Activity and SEC Form 4 Filings
TMBR insider trading summary
No open-market insider purchases or sales of Timber Pharmaceuticals, Inc. (TMBR) have been reported on SEC Form 4 in the past 12 months.
Latest TMBR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 15, 2021 | John Koconis | CEO & President | Buy | $8K (20,000 @ $0.38) |
| Nov 23, 2021 | Alan Mendelsohn | Chief Medical Officer | Buy | $5K (10,000 @ $0.47) |
| Nov 23, 2021 | Edward J Sitar | Director | Buy | $7K (15,000 @ $0.46) |
| Sep 2, 2021 | TardiMed Sciences LLC | 10% Owner | Sell | $211K (225,000 @ $0.94) |
| Sep 1, 2021 | TardiMed Sciences LLC | 10% Owner | Sell | $139K (150,500 @ $0.92) |
| Aug 31, 2021 | TardiMed Sciences LLC | 10% Owner | Sell | $137K (150,000 @ $0.91) |
| Aug 30, 2021 | TardiMed Sciences LLC | 10% Owner | Sell | $93K (100,000 @ $0.93) |
| Aug 26, 2021 | TardiMed Sciences LLC | 10% Owner | Sell | $92K (100,000 @ $0.92) |
| Aug 25, 2021 | TardiMed Sciences LLC | 10% Owner | Sell | $91K (100,000 @ $0.91) |
| Aug 24, 2021 | TardiMed Sciences LLC | 10% Owner | Sell | $93K (100,000 @ $0.93) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.